Enterprise Value

299M

Cash

223.8M

Avg Qtr Burn

-16.23M

Short % of Float

20.95%

Insider Ownership

3.14%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 1/2

Data readout

Phase 1/2

Data readout

CABA-201 (4-1BB CD19-CAR T) Details
Systemic lupus erythematosus, Lupus nephritis

Phase 1/2

Data readout

CABA-201 (4-1BB CD19-CAR T) Details
Idiopathic inflammatory myopathy / myositis, Anti-synthetase syndrome, Immune-mediated necrotizing myopathy, Dermatomyositis

Phase 1/2

Data readout

DSG3-CAART Details
Mucosal Pemphigus Vulgaris

Phase 1

Data readout

MuSK-CAART Details
Autoimmune disease, Myasthenia gravis

Phase 1

Data readout